海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
32件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients.
- Dyslipidemia MedDRA version: 9.1 Level: LLT Classification code 10020604 Term: Hypercholesterolemia
- Austria, France, Netherlands, Spain
- 2008-04-22
Authorised
- A clinical study to investigate the efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the prevention of Acute Graft-versus-Host-Disease in adult and pediatric patients after allogeneic hematopoietic stem cell transplant
- Prevention of Acute Graft-versus-Host Disease (aGvHD) after allogeneic hematopoietic stem cell transplant MedDRA version: 20.0 Level: LLT Classification code 10068908 Term: AGVHD System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Italy, Poland, Portugal, Spain, Turkey, United Kingdom, United States
- 2017-11-28
Authorised
- BI 425809 in patients with cognitive impairment due to Alzheimer's Disease.
- Cognitive impairment due to Alzheimer's Disease Patients with diagnosis of mild-to moderate Alzheimer's dementia according to the recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Austria, Canada, Finland, France, Germany, Greece, Hungary, Italy, Japan, Norway, Spain, United Kingdom, United States
- 2016-04-27
Authorised
- Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
- Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation MedDRA version: 20.0 Level: PT Classification code 10029547 Term: Non-Hodgkin's lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Austria, Belgium, Czech Republic, France, Germany, Israel, Netherlands, Poland, Portugal
- 2018-02-27
Authorised
- Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients with mild Alzheimer's Disease (STEADFAST)
- MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: HLT Classification code 10012268 Term: Dementia (excl Alzheimer's type) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012296 Term: Dementia of the Alzheimer's type, with depressed mood System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012295 Term: Dementia of the Alzheimer's type, with delusions System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012294 Term: Dementia of the Alzheimer's type, with delirium System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012293 Term: Dementia of the Alzheimer's type, uncomplicated System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10012292 Term: Dementia of the Alzheimer's type NOS System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10066571 Term: Progression of Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Canada, Ireland, New Zealand, South Africa, United Kingdom, United States
- 2016-06-07
Authorised
- DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL- TO-MILD ALZHEIMER’S DISEASE
- Alzheimer’s Disease (AD) MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Bulgaria, Canada, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2016-05-26
Authorised
- Estudio abierto y aleatorizado para evaluar la eficacia radiológica y la seguridad de Enbrel® (etanercept) añadido a metotrexato en comparación con el tratamiento habitual en pacientes con artritis reumatoide moderada An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoid Arthritis Disease Activity. - Extra
- Artritis reumatoide RHEUMATOID ARTHRITIS MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis
- Austria, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Spain, United Kingdom
- 2008-03-24
Authorised
- A clinical study performed at several sites with a treatment duration of 6 months, with 3 treatment arms (2 different dosages LM11A-31-BHS and 1 placebo), which are randomly distributed in a double-blind manner (neither physician nor patient will know which treatment arm) between the patients to evaluate safety, tolerability and other questions of research of the two different oral dosages of LM11A-31-BHS in comparison with placebo in patients with mild to moderate probable Alzheimer’s disease
- Mild to moderate Alzheimer's disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 MedDRA version: 19.0 Level: LLT Classification code 10066571 Term: Progression of Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Austria
- 2016-05-25
Authorised
- Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5)
- previously untreated acute myeloid leukemia (AML) or high risk myelodysplasie (MDS) MedDRA version: 18.1 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864 MedDRA version: 18.1 Level: LLT Classification code 10028532 Term: Myelodysplasia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Austria, Belgium, Estonia, Finland, Germany, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland
- 2013-11-13
Authorised
- DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL- TO-MILD ALZHEIMER?S DISEASE
- Alzheimer?s Disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Bulgaria, Canada, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2016-05-17